KeyCorp reiterated their buy rating on shares of Steris (NYSE:STE) in a research note issued to investors on Thursday. The firm currently has a $103.00 price objective on the medical equipment provider’s stock.

STE has been the topic of a number of other reports. Zacks Investment Research cut Steris from a buy rating to a hold rating in a research report on Wednesday, January 24th. Raymond James Financial reiterated a market perform rating and issued a $100.00 price target on shares of Steris in a research report on Wednesday, January 3rd. Northcoast Research set a $102.00 price target on Steris and gave the company a buy rating in a research report on Thursday. Finally, TD Securities upped their price target on Steris from C$14.00 to C$16.00 and gave the company a buy rating in a research report on Thursday, November 9th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of $84.80.

Steris (NYSE:STE) opened at $85.57 on Thursday. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.82 and a quick ratio of 2.18. The company has a market capitalization of $7,290.00, a price-to-earnings ratio of 30.13 and a beta of 1.22. Steris has a 12 month low of $66.84 and a 12 month high of $93.71.

Steris (NYSE:STE) last announced its quarterly earnings results on Wednesday, February 7th. The medical equipment provider reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $1.07 by $0.05. Steris had a return on equity of 11.57% and a net margin of 9.42%. The firm had revenue of $661.90 million for the quarter, compared to analysts’ expectations of $663.17 million. During the same period in the prior year, the business posted $0.98 earnings per share. The business’s revenue was up 2.3% compared to the same quarter last year. research analysts predict that Steris will post 4.13 EPS for the current fiscal year.

In other news, VP Sudhir K. Pahwa sold 2,000 shares of the stock in a transaction on Monday, January 29th. The stock was sold at an average price of $92.09, for a total transaction of $184,180.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP John Adam Zangerle sold 3,650 shares of the stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $88.00, for a total value of $321,200.00. The disclosure for this sale can be found here. Corporate insiders own 2.55% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. grew its holdings in shares of Steris by 3.4% during the fourth quarter. BlackRock Inc. now owns 7,184,409 shares of the medical equipment provider’s stock worth $628,419,000 after purchasing an additional 239,200 shares during the last quarter. State Street Corp grew its holdings in shares of Steris by 53.2% during the second quarter. State Street Corp now owns 2,336,074 shares of the medical equipment provider’s stock worth $190,392,000 after purchasing an additional 811,622 shares during the last quarter. Fisher Asset Management LLC boosted its holdings in Steris by 3.0% in the third quarter. Fisher Asset Management LLC now owns 1,539,157 shares of the medical equipment provider’s stock valued at $136,061,000 after acquiring an additional 45,191 shares during the last quarter. Bessemer Group Inc. boosted its holdings in Steris by 3.4% in the third quarter. Bessemer Group Inc. now owns 1,387,199 shares of the medical equipment provider’s stock valued at $122,630,000 after acquiring an additional 45,198 shares during the last quarter. Finally, American Century Companies Inc. boosted its holdings in Steris by 14.6% in the fourth quarter. American Century Companies Inc. now owns 1,194,167 shares of the medical equipment provider’s stock valued at $104,454,000 after acquiring an additional 152,346 shares during the last quarter. Institutional investors own 89.63% of the company’s stock.

WARNING: This report was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://theolympiareport.com/2018/02/12/steris-ste-earns-buy-rating-from-keycorp.html.

About Steris

STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.

Analyst Recommendations for Steris (NYSE:STE)

Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.